Study challenges traditional breast cancer classification methods

Breast most cancers is commonly labeled as both estrogen receptor-positive (hormone-sensitive) or not. Nevertheless, a brand new examine from Karolinska Institutet means that this simplified classification might overlook vital organic variations between sufferers that might have an effect on remedy selections. The outcomes are printed in The Lancet Regional Well being – Europe.

Breast most cancers tumors that categorical estrogen receptors are referred to as estrogen receptor-positive (ER-positive) or hormone-sensitive breast most cancers and, on common, have a greater prognosis than ER-negative breast most cancers. ER-positive tumors can develop in response to estrogen and might due to this fact be handled with medicine that block the results of this hormone.

It’s a spectrum

Internationally, tumors during which a minimum of one per cent of the tumor cells categorical the estrogen receptor are labeled as ER-positive, whereas in Sweden the edge is ten per cent.

Relatively than speaking about ER-positive or ER-negative breast most cancers, we have to view it as a spectrum. Our examine reveals {that a} extra detailed classification can present vital details about the tumor’s organic traits and the affected person’s prognosis.”

Balazs Acs, Affiliate Professor, Division of Oncology-Pathology, Karolinska Institutet

The researchers analyzed knowledge from over 75,000 ladies in Sweden who, between 2007 and 2023, had been identified with HER2-negative breast most cancers, a kind of most cancers that doesn’t have elevated ranges of the HER2 protein. The sufferers had been divided into 5 teams primarily based on the share of tumor cells expressing the estrogen receptor: 0, 1–9, 10–29, 30–59 or 60–100 per cent. The tumor traits, remedies and survival charges had been then in contrast throughout the teams. The researchers additionally analyzed molecular knowledge from nearly 4,800 tumors to check organic variations.

Could information remedy

Ladies whose tumors had low or reasonable ranges of estrogen receptors (as much as 59 per cent) had poorer survival charges than these whose tumors had excessive ranges (over 60 per cent). These variations remained even when the researchers took under consideration different vital components akin to tumor stage, age and remedy. tumors during which 10 to 29 per cent of the tumor cells expressed estrogen receptors had been biologically and clinically much like tumors with very low ranges or no estrogen receptors in any respect.

“We additionally noticed that sufferers with gentle to reasonable ranges of estrogen receptors seem to learn from a mix of chemotherapy and hormone remedy,” says Balazs Acs. “This implies that the precise degree of estrogen receptors could also be vital when selecting a remedy.”

The researchers emphasize that the outcomes come from an observational examine and that remedies weren’t randomly allotted amongst sufferers. Additional research are wanted to research how the findings can finest be translated into medical apply.

The examine was performed in collaboration with Karolinska College Hospital in Sweden.